Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript Summary
Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript Summary
Financial growth was particularly strong in the Pain portfolio, and Jornay PM is expected to generate over $100 million in net revenue in 2024.The following is a summary of the Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript:
以下是 Collegium Pharmaceutical, Inc. (COLL) 2024年第三季度业绩会 记要：
Financial Performance:
财务表现:
Collegium reported record total net product revenues of $159.3 million in Q3 2024, up 17% year-over-year.
Adjusted EBITDA was a record $105.1 million, up 18% year-over-year.
Financial growth was particularly strong in the Pain portfolio, and Jornay PM is expected to generate over $100 million in net revenue in 2024.
Collegium 报告2024年第三季度总净产品营业收入为15930万美元，同比增长17%。
调整后的EBITDA创下了10510万美元的记录，同比增长18%。
财务增长在疼痛产品组合方面表现尤为强劲，预计 Jornay Pm 在2024年将产生超过10000万美元的净收入。
Business Progress:
业务进展:
Completed the acquisition of Ironshore, integrating Jornay PM into the ADHD market.
Jornay PM prescriptions increased 31.2% year-over-year, highlighted by back-to-school season growth.
Introduced new CEO Vikram Karnani, a seasoned biopharmaceutical executive, to lead future growth and expansion.
完成了对Ironshore的收购，并将Jornay Pm整合到多动症市场中。
Jornay Pm处方同比增长31.2%，以返校季节增长为特色。
引入经验丰富的生物制药高管维克拉姆·卡纳尼担任新首席执行官，领导未来增长和扩张。
Opportunities:
机会：
Integration of Ironshore's Jornay PM broadens Collegium's commercial presence into the large ADHD market, enhancing revenue diversification beyond pain management.
将Ironshore的Jornay Pm整合到学院的商业业务中，拓展到庞大的ADHD市场，增强营业收入多元化，超越疼痛管理。
Risks:
风险：
No explicit risks detected.
没有发现任何明确风险。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。内容准确性无法完全保证。如需更全面详情，请参阅IR网站。本文仅供投资者参考，不具有任何指导或推荐建议。
